News - Insulin lispro
Eli Lilly and Company has announced a streamlining of a portion of its manufacturing operations in Indianapolis. Lilly is offering a voluntary exit program to employees in selected areas, with enhanced financial incentives for those who leave the company.
To: CITY EDITORS Contact: Phil Belt, +1-317-276-2506, or Edward Sagebiel, +1-317- 433-9899, both of Eli Lilly and Company INDIANAPOLIS, April 16 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced a streamlining of a portion of its manufacturing operations in Indianapolis.
INDIANAPOLIS, Feb. 21 /PRNewswire/ -- Completing an unprecedented year of innovation in insulin delivery devices, Eli Lilly and Company (LLY) today announced the launch of KwikPen(TM), a new insulin pen prefilled with the Humalog(R) (insulin lispro injection [rDNA origin]) brand of insulins.
INDIANAPOLIS, Jan. 11 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced several strategic changes to its global manufacturing operations to better support the company's current product portfolio and evolving drug pipeline.